8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - ZEVRA THERAPEUTICS filed an 8-K with the SEC on Nov 3 (a notice of a material company event).
Directly affected
- ZVRA Zevra Therapeutics
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Zevra Therapeutics belongs to, so it often moves with news about it.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+12.0% 30d
AbbVie is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+3.5% 30d
Merck is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+10.0% 30d
Abbott Laboratories is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ZVRA | +0.39% | +0.15% | base | +8.96% | +2.63% | +13.05% | +18.26% |
| XLV | -2.42% | +0.36% | base | +3.08% | +0.65% | +0.47% | +2.39% |
| LLY | -8.25% | +0.73% | base | +0.62% | -2.48% | -3.88% | +0.21% |
| JNJ | +2.19% | +2.93% | base | +3.82% | +2.34% | +3.82% | +5.99% |
| ABBV | +0.42% | +3.41% | base | +2.66% | +1.15% | +1.97% | +2.59% |
| MRK | -1.72% | +4.16% | base | +3.94% | +1.84% | +1.45% | +2.81% |
| ABT | -5.79% | -2.52% | base | +5.93% | +3.79% | +0.53% | +1.02% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-03 AccNo: 0001434647-26-000085 Size: 321 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Price since this story was published: Zevra Therapeutics (ZVRA)
| Company | When | Move | Status |
|---|---|---|---|
| AbbVie (ABBV) | that day | +2.66% | final price |
| AbbVie (ABBV) | the next day | +1.15% | final price |
| AbbVie (ABBV) | two days later | +1.97% | final price |
| AbbVie (ABBV) | three days later | +2.59% | final price |
| AbbVie (ABBV) | three days earlier | +3.41% | final price |
| AbbVie (ABBV) | five days earlier | +0.42% | final price |
| Abbott Laboratories (ABT) | that day | +5.93% | final price |
| Abbott Laboratories (ABT) | the next day | +3.79% | final price |
| Abbott Laboratories (ABT) | two days later | +0.53% | final price |
| Abbott Laboratories (ABT) | three days later | +1.02% | final price |
| Abbott Laboratories (ABT) | three days earlier | -2.52% | final price |
| Abbott Laboratories (ABT) | five days earlier | -5.79% | final price |
| Johnson & Johnson (JNJ) | that day | +3.82% | final price |
| Johnson & Johnson (JNJ) | the next day | +2.34% | final price |
| Johnson & Johnson (JNJ) | two days later | +3.82% | final price |
| Johnson & Johnson (JNJ) | three days later | +5.99% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +2.93% | final price |
| Johnson & Johnson (JNJ) | five days earlier | +2.19% | final price |
| Eli Lilly (LLY) | that day | +0.62% | final price |
| Eli Lilly (LLY) | the next day | -2.48% | final price |
| Eli Lilly (LLY) | two days later | -3.88% | final price |
| Eli Lilly (LLY) | three days later | +0.21% | final price |
| Eli Lilly (LLY) | three days earlier | +0.73% | final price |
| Eli Lilly (LLY) | five days earlier | -8.25% | final price |
| Merck (MRK) | that day | +3.94% | final price |
| Merck (MRK) | the next day | +1.84% | final price |
| Merck (MRK) | two days later | +1.45% | final price |
| Merck (MRK) | three days later | +2.81% | final price |
| Merck (MRK) | three days earlier | +4.16% | final price |
| Merck (MRK) | five days earlier | -1.72% | final price |
| Select Sector Spdr Tr (XLV) | that day | +3.08% | final price |
| Select Sector Spdr Tr (XLV) | the next day | +0.65% | final price |
| Select Sector Spdr Tr (XLV) | two days later | +0.47% | final price |
| Select Sector Spdr Tr (XLV) | three days later | +2.39% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | +0.36% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | -2.42% | final price |
| Zevra Therapeutics (ZVRA) | that day | +8.96% | final price |
| Zevra Therapeutics (ZVRA) | the next day | +2.63% | final price |
| Zevra Therapeutics (ZVRA) | two days later | +13.05% | final price |
| Zevra Therapeutics (ZVRA) | three days later | +18.26% | final price |
| Zevra Therapeutics (ZVRA) | three days earlier | +0.15% | final price |
| Zevra Therapeutics (ZVRA) | five days earlier | +0.39% | final price |
Congressional trades in the stocks in this story
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 14 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 27 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 34 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 39 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 27 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 50 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 60 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 40 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 76 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Rohit Khanna bought Abbott Laboratories (ABT) (held by a spouse), worth $1,001 - $15,000 on 7 Oct 2026. That is 27 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 32 days before publication. Filed 27 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Zevra Therapeutics (ZVRA)
Companies mentioned with this story
- ZVRA Zevra Therapeutics
Zevra Therapeutics (ZVRA) is linked, with no stored direction, high confidence in the 3 Nov 2026 story “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> ZVRA
- XLV Select Sector Spdr Tr
For “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer),” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR holds the health sector that Zevra Therapeutics belongs to, so it often moves with news about it
- LLY Eli Lilly
For “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer),” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news
- JNJ Johnson & Johnson
Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer).” Reason on file: Johnson & Johnson is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news
- ABBV AbbVie
AbbVie (ABBV) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer).” Reason on file: AbbVie is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news
- MRK Merck
In “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer),” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news
- ABT Abbott Laboratories
Abbott Laboratories (ABT) is linked, with no stored direction, medium confidence in the 3 Nov 2026 story “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer).” Reason on file: Abbott Laboratories is a peer of Zevra Therapeutics in pharmaceutical preparations; rivals often move on the same news
How “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)” reaches Zevra Therapeutics (ZVRA)
On 3 Nov 2026, “8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)” is the story that connects Zevra Therapeutics (ZVRA) to this story.
For Zevra Therapeutics (ZVRA), the reason on file says SEC 8-K filing -> direct issuer disclosure -> ZVRA
A second company, Select Sector Spdr Tr (XLV), is listed for a different reason: Health Care Select Sector SPDR holds the health sector that Zevra Therapeutics belongs to, so it often moves with news about it
Dates in the story, and the Zevra Therapeutics (ZVRA) price range
LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09. ZVRA traded between 10.15 and 11.19 across 2 sessions. The latest close on file is 11.17.
What the saved facts support for Zevra Therapeutics (ZVRA)
46 out of 100
“8-K - ZEVRA THERAPEUTICS, INC. (0001434647) (Filer)” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.